UCL Discovery
UCL home » Library Services » Electronic resources » UCL Discovery

Efficacy, Safety, and Pharmacodynamic Effects of the Bruton's Tyrosine Kinase Inhibitor, Fenebrutinib (GDC-0853), in Systemic Lupus Erythematosus

Isenberg, D; Furie, R; Jones, NS; Guibord, P; Galanter, J; Lee, C; McGregor, A; ... Tuckwell, K; + view all (2021) Efficacy, Safety, and Pharmacodynamic Effects of the Bruton's Tyrosine Kinase Inhibitor, Fenebrutinib (GDC-0853), in Systemic Lupus Erythematosus. Arthritis & Rheumatology , 73 (10) pp. 1835-1846. 10.1002/art.41811. Green open access

[thumbnail of Isenberg_art.41811.pdf]
Preview
Text
Isenberg_art.41811.pdf - Accepted Version

Download (13MB) | Preview

Abstract

BACKGROUND: Fenebrutinib (GDC-0853, FEN) is a non-covalent, oral, and highly selective inhibitor of Bruton's tyrosine kinase (BTK). The efficacy, safety, and pharmacodynamics of FEN were assessed in this randomized, placebo-controlled, multi-center phase II study. METHODS: Patients with moderate-to-severely active systemic lupus erythematosus on background standard of care therapy were randomized to placebo, FEN 150 mg QD, or FEN 200 mg BID arms. Corticosteroid taper was recommended from weeks 0 to 12 (W0-W12) and W24-W36. The primary endpoint was SRI-4 at W48. RESULTS: Patients (N=260) were enrolled from 44 sites in 12 countries, with the majority from Latin America, USA, and Western Europe. The SRI-4 response rates at W48 were 51% (p=0.37, versus placebo) for FEN 150 mg QD, 52% (p=0.34, versus placebo) for FEN 200 mg BID, and 44% for placebo. BICLA response rates at W48 were 53% (p=0.086, versus placebo) for FEN 150 mg QD, 42% (p=0.879, versus placebo) for FEN 200 mg BID, and 41% for placebo. Safety results were similar across all arms, although serious adverse events were more frequent with FEN 200 mg BID. By W48, patients treated with FEN had reduced levels of a BTK-dependent plasmablast RNA signature, anti-dsDNA autoantibodies, total IgG, and IgM, as well as increased complement C4, all relative to placebo. CONCLUSIONS: While FEN had an acceptable safety profile, the primary endpoint, SRI-4, was not met despite evidence of strong pathway inhibition.

Type: Article
Title: Efficacy, Safety, and Pharmacodynamic Effects of the Bruton's Tyrosine Kinase Inhibitor, Fenebrutinib (GDC-0853), in Systemic Lupus Erythematosus
Location: United States
Open access status: An open access version is available from UCL Discovery
DOI: 10.1002/art.41811
Publisher version: https://doi.org/10.1002/art.41811
Language: English
Additional information: This version is the author accepted manuscript. For information on re-use, please refer to the publisher's terms and conditions.
Keywords: Bruton’s kinase inhibitor, clinical trial, fenebrutinib, systemic lupus erythematosus
UCL classification: UCL
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Medicine
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Medicine > Inflammation
URI: https://discovery.ucl.ac.uk/id/eprint/10131264
Downloads since deposit
9Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item